4-[(2E)-2-(2-methoxybenzylidene)hydrazinyl]-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 4-[(2E)-2-(2-methoxybenzylidene)hydrazinyl]-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine
• 英文别名: N-[(E)-(2-methoxyphenyl)methylideneamino]-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-amine
• 化学式: C₁₈H₁₈N₄OS
• 分子量: 338.4
• InChiKey: LNPSRFXXZUNRRF-UFFVCSGVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  87.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] HYDRAZONE DERIVATIVES AND THEIR USE AS BETA SECRETASE INHIBITORS<br/>[FR] DERIVES D'HYDRAZONE ET LEUR UTILISATION COMME INHIBITEURS DE LA BETA-SECRETASE
  申请人：GENETICS CO INC

  公开号：WO2006029850A1

  公开（公告）日：2006-03-23

  The invention relates to compounds having the general formula (I) wherein R3 is selected from the group consisting of H, methyl and hydroxyalkyl, and wherein Z1 and Z2 are selected independently from one another from the group consisting of substituted or un­substituted phenyl, naphtyl, pyridinyl, pyrazolyl, pyramidinyl, pyrazidinyl, quinolinyl, iso-quinolinyl, coumarinyl, indolyl, thiazolyl and thiophenyl groups bearing substituents n R1 and m R2, wherein R1 and R2 which may be the same or are different from one another are selected from the group consisting of H, alkyl, cycloalkyl, -C02R4, -CONHR4, -CR4O, -SO2R4, -NR4-CO-R4, alkoxy, al­kylthio, -OH, -O-aryl, -O-cycloalkyl, -S-aryl, -S-cycloalkyl, hy­droxyalkyl, halogen, haloalkyl, haloalkoxy, -CN, -NO2, hydroxyal­ kylamine, aminoalkyl, alkylamine, aryl, heteroaryl and sulfona­mide, wherein R4 is selected from the group consisting of H, C1 to C6 branched or unbranched alkyl, aryl, cycloalkyl, alkoxy, hetero­cycloalkyl, -OH, -O-aryl, -O-alkyl, -O-cycloalkyl, aminoalkyl, alkylamine, aryl and heteroaryl, and wherein n and m are the num­bers of the substituents R1 and R2 in Z1 and Z2, respectively, which are in a range between 0 and 5, with the proviso that if n and m are integers higher than 2, R1 and/or R2 may form a fused aromatic or a carbocyclic or heterocyclic ring system, or a salt, or a physiologically functional derivative, or a prodrug thereof.

  该发明涉及具有一般式（I）的化合物，其中R3从H、甲基和羟基烷基组成的群中选择，Z1和Z2从取代或未取代的苯基、萘基、吡啶基、吡唑基、吡啶基、吡嗪基、喹啉基、异喹啉基、香豆素基、吲哚基、噻唑基和噻吩基中独立选择，这些基带有取代基n R1和m R2，其中R1和R2可以相同也可以不同，从H、烷基、环烷基、-C02R4、-CONHR4、-CR4O、-SO2R4、-NR4-CO-R4、烷氧基、烷硫基、-OH、-O-芳基、-O-环烷基、-S-芳基、-S-环烷基、羟基烷基、卤素、卤代烷基、卤代烷氧基、-CN、-NO2、羟基烷胺、氨基烷基、烷基胺、芳基、杂环芳基和磺酰胺组成的群中选择，其中R4从H、C1到C6支链或直链烷基、芳基、环烷基、烷氧基、杂环烷基、-OH、-O-芳基、-O-烷基、-O-环烷基、氨基烷基、烷基胺、芳基和杂环芳基中选择，n和m分别为Z1和Z2中取代基R1和R2的数量，范围在0到5之间，但如果n和m是大于2的整数，则R1和/或R2可以形成融合芳香族或碳环或杂环系统，或盐，或生理活性衍生物，或其前药。